Archive | Articles

PlasmaTech Appoints Leading Canadian Merchandiser to Board of Directors

Business Wire posted: 4 HOURS 42 MINUTES AGO
 
PlasmaTech, Inc. (Pink Sheets: PMAH), a wireless technology innovator providing solutions to the $120 billion global security market, announced today the appointment of Steve Malizia as an independent director on its Board. Malizia is owner and president of Detail Merchandising, Inc. (DM) (Burlington, Ontario) (www.dm-servicesinc.com), a master distributor of brand-name electrical products to the construction industry.

Founded in 1997, DM provides in-store merchandising services on behalf of major brands in some of the largest retail establishments in Canada, including major home improvement centers. Concurrently, Malizia is CEO of LCM Distribution Services Inc. (www.lcm-servicesinc.com), which offers a broad range of supply-chain management solutions, including value-added logistics, outsourcing and technology applications backed by in-house proprietary software. LCM operates a 30,000-square-foot, ISO 9001 certified facility for the assembly, packaging and kitting of third-party products. LCM provides retail merchandising services through its affiliate DM.

“In less than five years, Steve grew DM from a single-store electronics product distributor to one that services major national home improvement chains,” said PlasmaTech President Marvin Williams. “As a technology visionary, Steve lends us additional expertise in helping companies such as our reach their full sales potential.”

“I am impressed by PlasmaTech’s market intelligence in the area of wireless technologies. The Company’s first retail offering, the 2400CL keyless secured door lock, would be an ideal product offering for the many home improvement stores in the DM distribution channel. I look forward to helping PlasmaTech expand its marketing of this commercial-grade consumer product, along with other technology applications,” commented Steve Malizia.

About PlasmaTech, Inc.

PlasmaTech, Inc. is an innovator in the development, design, manufacturing and worldwide marketing of secure wireless solutions for consumer, industrial and government applications. PlasmaTech’s platform technology provides military-grade encryption security for the transmission of data, voice and video over wireless data communication links, offering extreme distances that were previously unachievable in the industry. Visit the Company’s website at www.plasmatechwireless.com.

Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend” and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in PlasmaTech’s filings with the Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to the ability of PlasmaTech to pay its debts to RF Wireless in order to retain title to PlasmaTech’s intellectual property, the ability of PlasmaTech to effectively manage the intellectual property acquired from RF Wireless and integrate it into the business of PlasmaTech, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on PlasmaTech’s website does not constitute a part of this release.

Amico Games Corp. Anticipates Substantial Growth in 2010 and 2011

Marketwire posted: 1 DAY 3 HOURS AGO
 
GUANGZHOU, CHINA — (Marketwire) — 01/12/10 — Amico Games Corp. (OTCBB: AMCG), an information technology company specializing in developing and operating mobile phone multiplayer networked games, anticipates significant growth in the Chinese mobile games industry. The market value of China’s burgeoning mobile phone game market is forecasted to be RMB 2.68 billion (or USD 394 million) in 2010 and may reach RMB 4.21 billion (or USD 619 million) in 2011 according to statistics released in 2009 by Analysys International.

“We increased our revenues almost 40% between our fiscal years of 2008 and 2009. We are very optimistic that we will continue this trend given the projected performance of mobile phone games in our market,” Mr. Peter Liu, Amico’s President and CEO commented. “The statistics released by Analysys International indicate the huge market opportunity that mobile phone gaming holds for the future. Additionally with consideration of our ongoing R&D plans and the outstanding performance of our JAVA game of Journey to the West Online, I believe that we will enjoy substantial growth in the near future.”

In 2008, the Chinese mobile phone game market value reached RMB 1.365 billion (or USD 200 million), an increase of 62.67% from 2007. Analysys International estimates that the compound growth rate will be 45.54% from 2008 to 2011. This booming market growth is due primarily to the rapid growth in mobile phone ownership, reaching over 660 million users in 2009, the expansion of 3G network availability and the improvements made by mobile phone game developers in creation of, operation and marketing capabilities of their product. According to Analysys International, JAVA games occupied 72% market share in 2008.

About Amico Games Corp.

Amico Games Corp. is a software company specializing in developing mobile phone games for the Chinese market. On December 31, 2009, Amico acquired Galaxy Software Limited is a Chinese private-owned company incorporated in November, 2001. Galaxy is one of the earliest mobile phone multiplayer game developers in China, as well as one of the first Chinese company to develop and operate Java(TM) MMRPOG (massive multiplayer role playing online games) mobile phone games. It is also the first company to provide multiplayer games over the WAP platform of China Mobile, the world’s largest mobile phone provider based upon subscribers. For more information, please visit the Amico’s website at: www.amicogames.com

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend” and similar expressions, as they relate to Amico or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results, including revenue and customer projections, could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of Amico’s products, the competitive environment within the industry, the ability of Amico to continue to expand its operations, the level of costs incurred in connection with Amico’s expansion efforts, economic conditions in the industry and the financial strength of Amico’s customers. Amico does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1151441

Echo Therapeutics to Present at OneMedForum 2010 Emerging Company Finance Conference

2010-01-07 07:00 ET – News Release

FRANKLIN, Mass., Jan. 7 /PRNewswire-FirstCall/ — Echo Therapeutics, Inc. , a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that Patrick T. Mooney, M.D., Chairman and Chief Executive Officer, will present at the OneMedPlace Finance Forum 2010 at 11.45 a.m. (PT) on Wednesday, January 13, 2010 at The Sir Francis Drake Hotel in San Francisco, CA.

Company management will be available for one-on-one meetings on January 12th and 13th. Please contact Brett Maas at (646) 536-7331 or brett@haydenir.com to request a meeting.

“Building on the significant positive momentum of 2009, we believe that we have set the stage for an exciting and productive 2010, as we enter the year with most of the initial product development work behind us and two significant strategic partnerships in place,” commented Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics. “We are now focused on completing milestone events, including key clinical trials, which will enable us to begin generating revenue. We anticipate near-term revenue for Echo from the royalties on Prelude disposables and lidocaine sales by Ferndale Pharma Group in the topical anesthetic market in the US and UK during 2010. Additionally, we are positioned to be ‘first-to-market’ with tCGM in the hospital critical care market and we estimate that the hospital market opportunity for continuous glucose monitoring is greater than $1 billion. Finally, we plan to develop our Symphony system for use in the consumer market, providing additional upside potential and partnership possibilities in this more than $10 billion market opportunity. We are excited to share our vision and discuss our future opportunities with investors at this conference.”

About the OneMedForum 2010

Held annually in San Francisco, the OneMedPlace Finance Forum was created to connect emerging healthcare and life science companies with investors and strategic partners. Over 100 company presentations will occur by some of the most promising – and typically least recognized – companies in the world. Recognizing the impacts and opportunities connected to healthcare reform and the stimulus package, the conference has added a third day dedicated to Health Information.

More information is available at http://www.onemedplace.com/onemedforum/index.php.

About Echo Therapeutics

Echo Therapeutics is focused on medical devices and specialty pharmaceuticals. Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo’s ongoing studies, including the efficacy of Echo’s Symphony tCGM System and Prelude SkinPrep System, the failure of future development and preliminary marketing efforts related to Echo’s Symphony tCGM System and Prelude SkinPrep System, Echo’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo’s ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM System and Prelude SkinPrep System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM System and its Prelude SkinPrep System. These and other risks and uncertainties are identified and described in more detail in Echo’s filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2008, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.

www.echotx.com

(C) 2002 – 2009 Echo Therapeutics, Inc. All rights reserved worldwide.

Echo Therapeutics, Inc.

Amico Engages Former Intel and Microsoft Software Developer for North American Expansion

Marketwire posted: 21 DAYS 10 HOURS AGO
 
SAN FRANCISCO, CA — (Marketwire) — 12/23/09 — Amico Games Corp. (OTCBB: AMCG), an information technology company specializing in developing and operating mobile phone multiplayer networked games, has engaged Michael Glass as its Director of North American Development. Mr. Glass will look for opportunities to expand Amico’s operations into North America through acquisition and licensing of applicable software for use in the Chinese market. To aid Mr. Glass in creating exposure for the company, Amico entered into an agreement for office premises in the center of North America’s software and information technology world: San Francisco.

Mr. Glass has over 20 years of experience in software development and has previously provided services for top companies such as British Telecom, Intel, Cisco Systems, Barclays and Microsoft. The Company anticipates that through Mr. Glass’ knowledge and experience in the software industry, as well as his vast network of contacts, the Company will be able to develop its presence in North America and take advantage of various technologies and products to increase its profitability in the Chinese market.

“I think Amico has a great future and I’m proud to be a part of developing the Company’s North American presence. North America has a lot of gaming technologies which I think will help Amico really grow its business in China,” stated Michael Glass.

About Amico Games Corp.

Amico Games Corp. is a software company specializing in developing mobile phone games for the Chinese market. Amico has entered into an agreement to acquire Galaxy Software Limited, a Chinese privately-owned company incorporated in November 2001. Galaxy is one of the earliest mobile phone multiplayer game developers in China, as well as one of the first Chinese companies to develop and operate Java(TM) MMRPOG (massive multiplayer role playing online games) mobile phone games. It is also the first company to provide multiplayer games over the WAP platform of China Mobile, the world’s largest mobile phone provider based upon subscribers. For more information, please visit the Amico’s website at:

www.amicogames.com

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend” and similar expressions, as they relate to Amico or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of Amico’s products, the competitive environment within the industry, the ability of Amico to continue to expand its operations, the level of costs incurred in connection with Amico’s expansion efforts, economic conditions in the industry and the financial strength of Amico’s customers and suppliers. Amico does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties. See Amico Games Corp.’s Current Report on Form 8-K regarding the share exchange agreement with Vodafun Limited, the parent company of Galaxy Software Limited, for details on various conditions which must be met before the share exchange between the two companies closes. There can be no assurance that the share exchange will close. Amico Games Corp. must issue 54,500,000 shares of its common stock to the current shareholder of Vodafun Limited in order to complete the share exchange. Accounting for the anticipated cancellation of 29,800,000 shares of its common stock, Amico will have 72,700,000 shares of common stock issued and outstanding upon the closing of the share exchange.

Echo Therapeutics Announces Major Milestone: The Completion Of Product Development Work Of Its Revolutionary, Patented Prelude(TM) SkinPrep System

PR Newswire posted: 2 DAYS 11 HOURS AGO
 
FRANKLIN, Mass., Jan 11 /PRNewswire-FirstCall/ — Echo Therapeutics, Inc. (OTC Bulletin Board : ECTE), a company developing the needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, announced today that the Company has completed the product development work for its Prelude SkinPrep System and now has the commercially ready product to be used in final clinical trials.

Echo anticipates that no further changes will be made to the Prelude SkinPrep System and that the current device will be the one used for sale, subject to FDA market clearance of the product. The final Prelude device replaces the prototype device used in earlier clinical trials and will be tested in the near-term in a study using LMX4 lidocaine cream which should form the basis for a 510-k filing with Ferndale Pharma Group for the enhanced delivery of lidocaine. The Company believes that the addressable market for enhanced, fast acting topical lidocaine exceeds $1 billion.

“The completion of the product development work on our Prelude SkinPrep System, our skin preparation platform technology used for both transdermal drug delivery and skin preparation prior to the application of the Symphony tCGM glucose biosensor represents one of the most important milestone events in the Company’s history,” stated Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics. “We are now prepared to complete our clinical validation and begin commercialization efforts in enhanced topical lidocaine delivery. This next generation skin preparation device incorporates substantial improvements beyond the prototype used in earlier studies. We anticipate testing Prelude with LMX4 anesthetic cream for enhanced local dermal anesthesia in the near-term and subsequently seeking 510-k market clearance from the FDA.”

The Company also anticipates that the completed Prelude will be tested in the near future with its recently completed one-piece, cost-effective, single-use Symphony tCGM glucose biosensor in patients with diabetes and critically ill patients who require aggressive glucose monitoring. Prelude incorporates Echo’s patented skin permeation control feedback technology into a comfortable, wireless, hand-held device used to prepare a small area of the skin for the non-invasive, biosensor and monitoring components of its Symphony tCGM system or for transdermal drug delivery.

About Echo Therapeutics

Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo’s and its partners’ ongoing studies, including the efficacy of the Symphony tCGM System and Prelude SkinPrep System, the failure of future development and preliminary marketing efforts related to the Symphony tCGM System and Prelude SkinPrep System, Echo’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo’s ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM System and Prelude SkinPrep System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to the Symphony tCGM System and the Prelude SkinPrep System. These and other risks and uncertainties are identified and described in more detail in Echo’s filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2008, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.

© 2002 – 2009 Echo Therapeutics, Inc. All rights reserved worldwide.

SOURCE Echo Therapeutics, Inc.

Medical Care Technologies Inc. Provides Corporate Update for Shareholders

Marketwire posted: 5 DAYS AGO
 
LONDON — (Marketwire) — 01/08/10 — Medical Care Technologies Inc. (OTCBB: MDCE) would like to provide its shareholders with a corporate update.

On October 6, 2009, MDCE entered into a non-binding Letter of Intent with Great Union Corporation, (”GUC”) a Hong Kong corporation, with the intent to acquire ownership of certain medical care products developed by GUC.

According to the LOI, MDCE will then complete the acquisition of these assets by issuing 57,300,000 to GUC, or GUC’s designees.

GUC is a company holding assets associated with the development and maintenance of secure information systems which increase access to medical resources services, education and wellness, pharmaceutical and nutriceutical products. Patricia Traczykowski, President of MDCE, is pleased to provide an update of the Company’s progress and recent corporate activities, as the Company moves from the oil and gas industry, into medical care technologies.

For the upcoming year the Company plans to focus on MDCE’s new business strategy, which is to commercialize the medical care technologies it anticipates acquiring through strategic alliances with leading, world class players in the health industry and it is our strategy to provide expertise in pharmaceutical and nutriceutical product development, in order to gain brand and market acceptance with established sales and distribution channels. This strategy is intended to secure revenues, optimize cash flow and protect intellectual property rights through unique profit sharing partnerships as well as minimize capital and operational expenditures.

Patricia Traczykowski, President of MDCE, states, “We have set near term goals to imminently complete the acquisition and close the deal with GUC. This will lead MDCE to commercialization partnerships for GUC’s technologies and for each of its three divisions: Medical Devices, Pharmaceuticals and Nutriceuticals, in an effort to create the best possible value for our shareholders.”

Subsequently, on October 13, 2009, the Company filed Articles of Merger with the Nevada Secretary of State to effect a merger with its wholly owned subsidiary, Medical Care Technologies Inc., and assume the subsidiary’s name. The subsidiary was incorporated entirely for the purpose of effecting this name change and the merger did not affect the Company’s Articles of Incorporation or corporate structure in any other way. In conjunction with the name change the Company has also been granted a new trading symbol. The Company’s new trading symbol is: MDCE.

Subject to the execution of a definitive agreement and fulfillment of other conditions laid out in the agreement, MDCE’s current President, CEO and director, Patricia Traczykowski, shall resign from these positions to allow the Company to grow into the space of medical care technologies.

About Medical Care Technologies Inc.

Medical Care Technologies Inc. (www.medicaretech.com) is traded under the symbol MDCE on the OTCBB and is based in London, England. The Company is in the process of moving its portfolio of oil resources into medical care technologies. The products/services that the company hopes to acquire will constitute a healthcare delivery and wellness site dedicated to helping Asian consumers live healthier, more balanced lives. MDCE is planning to provide advanced connectivity, internationally standardized and secure business, technology and information systems to assist the Asian health industry — physicians, pharmacists, medical institutions, consumers — access medical resources, health services, education, wellness and pharmaceutical products throughout Asia. MDCE is planning to distribute and provide services at a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Nutriceuticals.

Further information on the Company can be found at www.sec.gov and the company’s website at www.medicaretech.com

Safe Harbor Statement

All statements contained in this press release, other than statements of historical fact, are forward-looking statements, including those regarding: MDCE’s products, services, capabilities, performance, opportunities, development and business outlook, guidance on our future financial results and other projections or measures of our future performance; the amount and timing of the benefits expected from strategic initiatives and acquisitions or from deployment of new or updated technologies, products, services or applications; and other potential sources of additional revenue. These statements are based on our current plans and expectations and involve risks and uncertainties that could cause actual future events or results to be different than those described in or implied by such forward-looking statements. These risks and uncertainties include those relating to: lack of operating history, transitioning from a development company to an operating company, difficulties in distinguishing MDCE’s products and services, ability to deploy MDCE’s services and products, market acceptance of our products and services; operational difficulties relating to combining acquired companies and businesses; our ability to form and maintain mutually beneficial relationships with customers and strategic partners; changes in economic, political or regulatory conditions or other trends affecting the healthcare, Internet, information technology and healthcare and pharmaceutical industries, and our ability to attract and retain qualified personnel. Other risks and uncertainties may include, but are not limited to: lack of or delay in market acceptance and fluctuations in customer demand, dependence on a limited number of significant customers, reliance on third party vendors and strategic partners, ability to meet future capital requirements on acceptable terms, continuing uncertainty in the global economy, and compliance with federal and state regulatory requirement. Further information about these matters can be found in our Securities and Exchange Commission filings. We expressly disclaim any intent or obligation to update these forward-looking statements. There can be no assurance that the acquisition of GUC’s assets will close. MDCE must issue 57,300,000 shares of its common stock to GUC, or GUC’s designees in order to close the acquisition. Accounting for the anticipated cancelation of 57,300,000 shares by Patricia Traczykowski, MDCE will have 98,900,000 shares of its common stock issued and outstanding upon the closing of the acquisition.

Medical Care Technologies Inc. Announces Appointment of New CEO

Marketwire posted: 1 DAY 1 HOUR AGO
 
LONDON — (Marketwire) — 01/12/10 — Medical Care Technologies Inc. (OTCBB: MDCE) today announced that Ning C. Wu has joined MDCE as its new President, Chief Executive Officer, and Chief Financial Officer effective immediately.

Ms. Wu is a seasoned entrepreneur with over 25 years’ experience in both the public and private sectors. Since 1995, in Toronto, Ontario, Ms. Wu served as Partner and Chief Executive Officer of GroupIT, a private information technology and services firm specializing in complete internet-intranet design, web database development, E-business and secure technology support to private, public and government sectors in Canada.

Most recently, Ms. Wu has been a Partner and Chief Executive Officer of Open Planet Enterprise Inc., which is a private professional services firm based in Toronto, Ontario that is providing business advice, business solutions and management services to Chinese companies aiming to do business in North America and North American companies aiming to do business in China.

“Medical Care Technologies Inc. is pleased to welcome Ms. Wu to the Company. As a seasoned executive, her leadership skills and experience as well as her connection to the Asian markets will be invaluable as the Company evolves,” states Patricia Traczykowski.

Michael Freeberg, one of the Company’s directors, was appointed as Treasurer of the Company.

Effective immediately Patricia Traczykowski will be resigning as the Company’s President, Chief Executive Officer, Treasurer, Chief Financial Officer, and Principal Accounting Officer but will remain on as a director.

About Medical Care Technologies Inc.

Medical Care Technologies Inc. (www.medicaretech.com) is traded under the symbol MDCE on the OTCBB and is based in London, England. The Company is in the process of moving its portfolio of oil resources into medical care technologies. The products/services that the company hopes to acquire are intended will constitute a healthcare delivery and wellness site, dedicated to helping Asian consumers live healthier, more balanced lives. MDCE is planning to provide advanced connectivity, internationally standardized and secure business, technology and information systems to assist the Asian health industry — physicians, pharmacists, medical institutions, consumers — in accessing medical resources, health services, education, wellness and pharmaceutical products throughout Asia. MDCE is planning to distribute and provide services at a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Nutriceuticals. Further information on the Company can be found at www.sec.gov and the company’s website at www.medicaretech.com

Safe Harbor Statement

All statements contained in this press release, other than statements of historical fact, are forward-looking statements, including those regarding: MDCE’s products, services, capabilities, performance, opportunities, development and business outlook, guidance on our future financial results and other projections or measures of our future performance; the amount and timing of the benefits expected from strategic initiatives and acquisitions or from deployment of new or updated technologies, products, services or applications; and other potential sources of additional revenue. These statements are based on our current plans and expectations and involve risks and uncertainties that could cause actual future events or results to be different than those described in or implied by such forward-looking statements. These risks and uncertainties include those relating to: lack of operating history, transitioning from a development company to an operating company, difficulties in distinguishing MDCE’s products and services, ability to deploy MDCE’s services and products, market acceptance of our products and services; operational difficulties relating to combining acquired companies and businesses; our ability to form and maintain mutually beneficial relationships with customers and strategic partners; changes in economic, political or regulatory conditions or other trends affecting the healthcare, Internet, information technology and healthcare and pharmaceutical industries, and our ability to attract and retain qualified personnel. Other risks and uncertainties may include, but are not limited to: lack of or delay in market acceptance and fluctuations in customer demand, dependence on a limited number of significant customers, reliance on third party vendors and strategic partners, ability to meet future capital requirements on acceptable terms, continuing uncertainty in the global economy, and compliance with federal and state regulatory requirement. Further information about these matters can be found in our Securities and Exchange Commission filings. We expressly disclaim any intent or obligation to update these forward-looking statements. There can be no assurance that the acquisition of GUC’s assets will close. MDCE must issue 57,300,000 shares of its common stock to GUC, or GUC’s designees in order to close the acquisition. Accounting for the anticipated cancelation of 57,300,000 shares by Patricia Traczykowski, MDCE will have 98,900,000 shares of its common stock issued and outstanding upon the closing of the acquisition.

Medical Care Technologies, Inc. Secures Financing

Marketwire posted: 3 HOURS 46 MINUTES AGO
 
LONDON — (Marketwire) — 01/13/10 — Medical Care Technologies, Inc. (OTCBB: MDCE) announces that it has completed a non-brokered private placement of 500,000 units at a price of US$0.20 per unit for total proceeds of US$100,000.

Each unit purchased is of one share of common stock, and one Series A Warrant. Each Series A Warrant is convertible into one share of common stock upon payment of $0.15 each. Each Series A Warrant is non-transferable. The Series A Warrants are exercisable for a period of 24 months from January 15, 2010.

“The funds raised from this placement shall be used for MDCE’s first Telehealth Care Center which will act as our flagship clinic in China, that will educate and treat patients via the Tele-Health(TM) Suite,” states Ning Wu, President of MDCE.

The units were sold pursuant to the exemption from registration contained in Regulation S of the Securities Act of 1933 in that the transaction took place outside the United States of America and the purchaser was a non-US person as defined in Regulation S. The securities that comprise the units are “restricted securities” as that term is defined in Rule 144 of the Securities Act of 1933.

About Medical Care Technologies, Inc.

Medical Care Technologies, Inc. (www.medicaretech.com) is traded under the symbol MDCE on the OTCBB and is based in London, England. The Company is in the process of moving its portfolio of oil resources into medical care technologies. The products/services that the company hopes to acquire are intended to constitute a healthcare delivery and wellness site, dedicated to helping Asian consumers live healthier, more balanced lives. MDCE is planning to provide advanced connectivity, internationally standardized and secure business technology and information systems to assist the Asian health industry — physicians, pharmacists, medical institutions, consumers, access medical resources, health services, education, wellness and pharmaceutical products throughout Asia. MDCE is planning to distribute and provide services at a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Nutraceuticals. Further information on the Company can be found at www.sec.gov and the company’s website at www.medicaretech.com

Safe Harbor Statement

All statements contained in this press release, other than statements of historical fact, are forward-looking statements, including those regarding: MDCE’s products, services, capabilities, performance, opportunities, development and business outlook, guidance on our future financial results and other projections or measures of our future performance; the amount and timing of the benefits expected from strategic initiatives and acquisitions or from deployment of new or updated technologies, products, services or applications; and other potential sources of additional revenue. These statements are based on our current plans and expectations and involve risks and uncertainties that could cause actual future events or results to be different than those described in or implied by such forward-looking statements. These risks and uncertainties include those relating to: lack of operating history, transitioning from a development company to an operating company, difficulties in distinguishing MDCE’s products and services, ability to deploy MDCE’s services and products, market acceptance of our products and services; operational difficulties relating to combining acquired companies and businesses; our ability to form and maintain mutually beneficial relationships with customers and strategic partners; changes in economic, political or regulatory conditions or other trends affecting the healthcare, Internet, information technology and healthcare and pharmaceutical industries, and our ability to attract and retain qualified personnel. Other risks and uncertainties may include, but are not limited to: lack of or delay in market acceptance and fluctuations in customer demand, dependence on a limited number of significant customers, reliance on third party vendors and strategic partners, ability to meet future capital requirements on acceptable terms, continuing uncertainty in the global economy, and compliance with federal and state regulatory requirement. Further information about these matters can be found in our Securities and Exchange Commission filings. We expressly disclaim any intent or obligation to update these forward-looking statements. There can be no assurance that the acquisition of GUC’s assets will close. MDCE must issue 57,300,000 shares of its common stock to GUC, or GUC’s designees in order to close the acquisition. Accounting for the anticipated cancelation of 57,300,000 shares by Patricia Traczykowski, MDCE will have 98,900,000 shares of it common stock issued and outstanding upon the closing of the acquisition.

Andes Gold to Begin Tailings Operations

Marketwire posted: 6 DAYS 3 HOURS AGO
 
NEW YORK, NY — (Marketwire) — 01/07/10 — Andes Gold Corporation. (PINKSHEETS: AGCZ) announced today that it is to begin Phase I preliminary assessment of its tailing operations.

The company is proceeding with its Phase I preliminary assessment of its tailing operations after accumulating 5000 tonnes of tailings from several months’ production on its own properties as well as several neighboring operations. It is anticipated that there will be an approximate return of 3.5 grams of Gold per tonne of tailings with an approximate gross value of $700,000 at current bullion prices. This is in addition to the company’s regular production.

“This preliminary assessment of the tailings operation is anticipated to be very profitable for the company and we believe we will be in full tailings operation within the next several months,” stated Alex Diaz, President of Andes Gold.

Andes Gold Corporation is a gold producing and exploration company with operations in Ecuador, (South America). In the post market melt-down of 2008 the world took shelter in the security of gold pushing the value to over $1,100 USD per ounce by January, 2010. Producing gold properties such as Andes Gold will continue to enjoy increased prosperity which can only improve if the price continues to climb.

About Andes Gold Corporation:

Andes Gold Corporation is a United States of America registered public company currently operating a gold mining and exploration corporation, through its wholly owned subsidiary company Compania Minera PLS.A. In Ecuador, (South America) which controls a Gold mining and exploration concession called the Miranda Alto. For more information please visit: www.andesgold-ir.com

Important Information:

About Forward-Looking Statements: Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend” and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company’s website does not constitute a part of this release.

Andes Gold to Acquire Roman Mine

Marketwire posted: 5 DAYS 3 HOURS AGO
 
NEW YORK, NY — (Marketwire) — 01/08/10 — Andes Gold Corporation. (PINKSHEETS: AGCZ) announced today that it has opened final discussions to acquire the “Roman Mine,” a neighboring property.

The company is pleased to announce that the negotiations for the strategic acquisition of the “Roman Mine” are well underway; discussions started in July of 2009. The property has huge advantages to the company as it has an additional access road, site for an expanded work camp and will add a new access tunnel making three tunnels in total. The company expects to conclude this acquisition on or before February, however several milestones including feasibility study and long range production goals need to be completed as part of the due diligence process.

“The acquisition of the Roman Mine will add two new virgin gold veins of ore production,” stated Alex Diaz, President of Andes Gold.

Andes Gold Corporation is a gold producing and exploration company with operations in Ecuador (South America). In the post market meltdown of 2008 the world took shelter in the security of gold pushing the value to over $1,100 USD per ounce by January 2010. Producing gold properties such as Andes Gold will continue to enjoy increased prosperity which can only improve if the price continues to climb.

About Andes Gold Corporation:

Andes Gold Corporation is a United States of America registered public company currently operating a gold mining and exploration corporation, through its wholly owned subsidiary company Compania Minera PLS.A. in Ecuador, (South America) which controls a Gold mining and exploration concession called the Miranda Alto. For more information please visit: www.andesgold-ir.com

Important Information:

About Forward-Looking Statements: Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend” and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company’s website does not constitute a part of this release.

Join Here
Join Here

PICKS-to-PHONE

On the go? Get our exploding picks delivered to your phone!

Phone number

Carrier

*Standard text messaging rates may apply from your carrier*

Watchlist

JBL11.73  chart +2.89%
ERTS16.46  chart +0.61%
JPM39.17  chart +2.65%
APDN0.00  chart +2.65%
HRRN0.00  chart +2.65%
SMWF0.00  chart +2.65%
BEHL0.00  chart +2.65%
EMGE0.00  chart +2.65%
RBTI0.00  chart +2.65%
JAGR0.00  chart +2.65%
MDOR0.00  chart +2.65%
MRI-B13.44  chart +0.00%
VSMR0.00  chart +0.00%
BONZ0.00  chart +0.00%
NYMH0.00  chart +0.00%
EMGE0.00  chart +0.00%
RBTI0.00  chart +0.00%
LUNA1.90  chart -0.52%
ADSX0.00  chart -0.52%
MDOR0.00  chart -0.52%
BMGP0.00  chart -0.52%
GTLA0.00  chart -0.52%
MRI-B13.44  chart +0.00%
HRRN0.00  chart +0.00%
RJF24.95  chart +2.21%
ATPG12.20  chart +6.09%
PALM0.00  chart +6.09%
DDRJB0.00  chart +6.09%
JPMJX0.00  chart +6.09%
MSJH0.00  chart +6.09%
FREAX17.06  chart +1.37%
2010-09-03 16:00